ECOG randomized patients with advanced NSCLC to 1 of 4 new 3 of the 4 regimens used in ECOG docetaxel/cisplatin, paclitaxel/cisplatin. In the ECOG trial, the only direct comparison of similar regimens, response rates and survival times were similar between patients treated with cisplatin. ECOG was chosen as a plenary session presentation because it is an important trial that reflects the state of care in of metastatic NSCLC—the.
|Published (Last):||25 October 2005|
|PDF File Size:||19.35 Mb|
|ePub File Size:||1.25 Mb|
|Price:||Free* [*Free Regsitration Required]|
In a series of more than patients with inoperable lung cancer analysed more than two decades ago to investigate the impact on survival of 50 prognostic factors, performance status, extent of disease and weight loss were among the most important prognostic factors [ 19 ].
Unfortunately, however, no data on first-line treatments are currently available. A Review James R. Platinum-based combination chemotherapy is currently recommended as the standard treatment for patients with advanced non-small-cell lung cancer NSCLCbut its benefit seems limited to fit patients with a performance status PS of 0 or 1.
Have we made any progress in the treatment of advanced non-small cell lung cancer NSCLC over the past 15 years?
The combination of cisplatin and vinorelbine was superior in terms of survival to vindesine—cisplatin and to vinorelbine alone. Moreover, it is a widely held opinion that these unfit patients are at higher risk for severe toxicity, which would counterbalance the eventual small benefit expected.
Grade 3 or 4 toxicities were fairly evenly distributed among treatments. As expected, platinum-based treatment is often associated with a higher occurrence of toxicity [ 3842 ].
Nonhematologic toxicities were generally similar between the two groups with the exception of more diarrhea in the irinotecan arm.
Taxane-Platinum Combinations in Advanced Non-Small Cell Lung Cancer: A Review
Docetaxel is also commonly used as part of a combined modality regimen in locally or regionally advanced disease, with notable results as consolidation therapy. Analysis of adverse events among the four phase III trials also revealed differentiating features. Would prophylactic irradiation to the mediastinum prevent fatal hemoptysis? Baseline characteristics were well balanced across treatment groups.
As our use of these taxane-platinum combinations expands, these differences in survival, response rate, adverse events, and QOL will permit us ecig better balance our treatment goals 5194 all patients with all stages of NSCLC. This secondary analysis showed that the significant advantage obtained with the combination of cisplatin and vinorelbine is predominantly limited to fit patients: In the s, platinum compounds were combined with newer third-generation chemotherapy agents, such as vinorelbine and gemcitabine, and the taxanes docetaxel and paclitaxel.
First, the current study allowed patients with brain metastases to participate.
Clearly we have reached our limit in developing doublet platinum-based combinations for advanced NSCLC. Semin Oncol ; 28 suppl 2: Despite the recognised priority to include these end points in studies for patients with advanced NSCLC our review showed that ecov data are hardly available. Recent randomised trials of platinum-free versus platinum-based combination chemotherapy in advanced NSCLC. These data should of course be kept in mind when treating PS2 patients, who are at a higher risk of toxicity.
Prognostic factors for eecog in patients with inoperable lung cancer. These are important studies to compare because they were conducted at nearly the same time and in very similar though not identical patient populations. Abstracts from proceedings of the most important oncology meetings, not yet published as full papers, were also considered.
Lung Cancer Highlights
Patient characteristics were reflective of the standard population ecg patients in advanced lung cancer trials. Regarding the choice of end points in clinical trials, it should be considered that symptomatic improvement is strongly requested by the patients. Patients strongly need symptomatic improvement: The study confirmed a substantial incidence of grade 3 and grade 4 toxicities in PS2 patients, although not significantly higher than in patients with better PS.
Compared with PC, grade 3 or 4 thrombocytopenia, anemia, and renal toxicity were more common with GC, and febrile neutropenia was less common.
Docetaxel Taxotere shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: Like topotecan, irinotecan is a topoisomerase I inhibitor with good activity in patients with ecoh cancer. PS2 patients reported the worst scores at baseline assessment. The role of chemotherapy in PS2 patients.
Prognostic factors for short-term survival in patients with stage IV non-small cell lung cancer.